Lutz F. Tietze
Tumour-selective chemotherapy must be based on the exploitation of phenotypic or genetic differences of malignant and normal cells. A promising approach is the antibody directed enzyme prodrug therapy (ADEPT) in which a conjugate of an enzyme and a monoclonal antibody binding to tumour associated antigens is used to convert a non-toxic prodrug into a toxic species selectively at the surface of malignant cells. We have developed novel glycosidic prodrugs such as 2 based on the biologically highly active antibiotic CC-1065 1 which is a potent cytotoxic compound with an ED50 of about 30 pM.
- Review: L.F. Tietze and T. Feuerstein, Aust. J. Chem. 2003, 56, 841-854.